James Bradner
James Bradner
Novartis Institutes for BioMedical Research
Verified email at
Cited by
Cited by
Selective inhibition of BET bromodomains
P Filippakopoulos, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, ...
Nature 468 (7327), 1067-1073, 2010
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ...
Cell 146 (6), 904-917, 2011
Selective inhibition of tumor oncogenes by disruption of super-enhancers
J Lovén, HA Hoke, CY Lin, A Lau, DA Orlando, CR Vakoc, JE Bradner, ...
Cell 153 (2), 320-334, 2013
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
J Zuber, J Shi, E Wang, AR Rappaport, H Herrmann, EA Sison, D Magoon, ...
Nature 478 (7370), 524-528, 2011
HDAC2 negatively regulates memory formation and synaptic plasticity
JS Guan, SJ Haggarty, E Giacometti, JH Dannenberg, N Joseph, J Gao, ...
Nature 459 (7243), 55-60, 2009
Transcriptional amplification in tumor cells with elevated c-Myc
CY Lin, J Lovén, PB Rahl, RM Paranal, CB Burge, JE Bradner, TI Lee, ...
Cell 151 (1), 56-67, 2012
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ...
Science 343 (6168), 305-309, 2014
Phthalimide conjugation as a strategy for in vivo target protein degradation
GE Winter, DL Buckley, J Paulk, JM Roberts, A Souza, S Dhe-Paganon, ...
Science 348 (6241), 1376-1381, 2015
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
JM Stommel, AC Kimmelman, H Ying, R Nabioullin, AH Ponugoti, ...
Science 318 (5848), 287-290, 2007
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase …
P Bali, M Pranpat, J Bradner, M Balasis, W Fiskus, F Guo, K Rocha, ...
Journal of Biological Chemistry 280 (29), 26729-26734, 2005
Direct inhibition of the NOTCH transcription factor complex
RE Moellering, M Cornejo, TN Davis, CD Bianco, JC Aster, SC Blacklow, ...
Nature 462 (7270), 182-188, 2009
Transcriptional addiction in cancer
JE Bradner, D Hnisz, RA Young
Cell 168 (4), 629-643, 2017
Chemical phylogenetics of histone deacetylases
JE Bradner, N West, ML Grachan, EF Greenberg, SJ Haggarty, T Warnow, ...
Nature chemical biology 6 (3), 238-243, 2010
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ...
Cancer research 67 (24), 11924-11932, 2007
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma
B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ...
Cancer cell 24 (6), 777-790, 2013
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima, JE Bradner, J Wong, D Chauhan, P Richardson, ...
Proceedings of the National Academy of Sciences 102 (24), 8567-8572, 2005
YY1 is a structural regulator of enhancer-promoter loops
AS Weintraub, CH Li, AV Zamudio, AA Sigova, NM Hannett, DS Day, ...
Cell 171 (7), 1573-1588. e28, 2017
R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling
R Su, L Dong, C Li, S Nachtergaele, M Wunderlich, Y Qing, X Deng, ...
Cell 172 (1-2), 90-105. e23, 2018
Targeting MYCN in neuroblastoma by BET bromodomain inhibition
A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ...
Cancer discovery 3 (3), 308-323, 2013
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
S Gröschel, MA Sanders, R Hoogenboezem, E de Wit, BAM Bouwman, ...
Cell 157 (2), 369-381, 2014
The system can't perform the operation now. Try again later.
Articles 1–20